真实世界尿液初段自采样hrHPV检测与宫颈样本准确性对比
VALHUDES是一项诊断准确性研究,比较自采样与医生采样检测高级别宫颈癌前病变(CIN2+)的临床准确性,疾病结局由阴道镜和病理评估。采用Abbott RealTime High Risk HPV检测分析Colli-Pee采集的初段尿,以宫颈结局为对照,使用宫颈样本预设Cut-off(CN≤32)时,尿液hrHPV检测CIN2+的相对敏感度为0.95(95%CI 0.88-1.01),相对特异度为1.03(95%CI 0.95-1.13)。
要点
- 初段尿hrHPV检测CIN2+的敏感度与特异度与宫颈样本相近
- 30岁及以上亚组相对敏感度0.97(95%CI 0.89-1.05)
- 探索性Cut-off(CN≤33.86)可进一步提高敏感度与分析性能
核心结论
- 基于初段尿的hrHPV-DNA PCR检测对CIN2+的检出准确性,与医生采集的宫颈样本相近。
研究设计与样本
- VALHUDES为诊断准确性研究(NCT03064087),比较自采样与医生采样样本的hrHPV检测对CIN2+的临床准确性。
- 疾病结局由阴道镜和组织学评估,以宫颈结局为对照评估Abbott RealTime High Risk HPV检测在Colli-Pee初段尿中的表现。
主要发现
- 使用宫颈样本预设Cut-off(CN≤32)时,尿液hrHPV检测CIN2+的相对敏感度为0.95(95%CI 0.88-1.01)。
- 该Cut-off下相对特异度为1.03(95%CI 0.95-1.13)。
- 30岁及以上女性亚组相对敏感度为0.97(95%CI 0.89-1.05),相对特异度为1.02(95%CI 0.93-1.12)。
- 探索性Cut-off(CN≤33.86)进一步提高了敏感度和检测分析性能。
关键数值与推荐
- 尿液hrHPV检测尚无经临床验证的Cut-off,研究采用宫颈样本预设Cut-off(CN≤32)。
- 探索性Cut-off为CN≤33.86。
临床怎么用
- 提示居家采集初段尿行hrHPV PCR检测可作为宫颈癌筛查的候选采样方式,准确性数据支持进一步临床验证。
局限性
- 尿液检测尚无经临床验证的Cut-off,主分析借用宫颈样本阈值。
- 探索性Cut-off为探索性分析,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Urine self-sampling has gained increasing interest for cervical cancer screening. In contrast to analytical performance, little information is available regarding the clinical accuracy for high-risk Human Papillomavirus (hrHPV) testing on urine. METHODS: VALHUDES is a diagnostic test accuracy study comparing clinical accuracy to detect high-grade cervical precancer (CIN2+) of HPV testing on self-collected compared to clinician-collected samples (NCT03064087). Disease outcome was assessed by colposcopy and histology. The Abbott RealTime High Risk HPV assay performance was evaluated on Colli-Pee collected first-void urine with cervical outcomes as comparator. RESULTS: As no assay cut-off for urine has been clinically validated, we used the predefined cut-off for cervical samples (CN ≤ 32). Using this cut-off, hrHPV testing was similarly sensitive (relative sensitivity 0.95; 95% CI: 0.88-1.01) and specific (relative specificity 1.03; 95% CI: 0.95-1.13) for detection of CIN2+ compared to testing cervical samples. In the subgroup of women of 30 years and older, similar relative sensitivity (0.97; 95% CI: 0.89-1.05) and specificity (1.02; 95% CI: 0.93-1.12) was found. Additionally, an exploratory cut-off (CN ≤ 33.86) was defined which further improved sensitivity and analytical test performance. CONCLUSION: HrHPV-DNA based PCR testing on home-collected first-void urine has similar accuracy for detecting CIN2+ compared to cervical samples taken by a clinician.
引用
- Van Keer S, Peeters E, Vanden Broeck D, et al. Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol. Gynecol Oncol. 2021. PMID: 34172287. doi:10.1016/j.ygyno.2021.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。